Drug intelligence / Profile preview

Lu AF88434

Development stage: Phase 1
Lead developer: Lundbeck
Modality: Small Molecules
Administration: Intravenous

Overview

Lu AF88434 is a novel small molecule inhibitor of phosphodiesterase type 1, specifically targeting the PDE1B subtype, which is naturally present in the human brain. It was developed by Lundbeck for potential use in neuropsychiatric disorders, particularly for treating disordered thinking associated with conditions such as schizophrenia and mild cognitive impairment. The drug has been studied using PET imaging to assess its uptake and distribution in the brain of healthy volunteers. Development for mild cognitive impairment has been discontinued.

Targets

PDE1B (Phosphodiesterase 1B, calmodulin-dependent)

Beyond the preview

Go deeper on Lu AF88434.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lu AF88434.

Explore the full profile